Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 02 tags : Trial save search
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
Published: 2021-08-02 (Crawled : 21:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 0.62%
H: 1.9%
C: 1.66%
disease phase 2 trial phase 2b
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
Published: 2021-08-02 (Crawled : 21:00) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 1.7M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: -3.32%
treatment phase 1 therapy trial t-cell car-t
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Published: 2021-08-02 (Crawled : 17:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.16%
IONS | $42.45 1.46% 1.45% 730K
|
Health Technology
|
| O: 0.24%
H: 2.2%
C: 1.07%
cardiovascular cardio trial enroll
Global Bispecific Antibody Therapeutics Market Forecast Clinical Trials Drug Approval Insight 2028
Published: 2021-08-02 (Crawled : 15:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 0.15%
H: 1.54%
C: -1.38%
clinical trials antibody drug trial approval
Watsco to Present at the Jefferies 2021 Virtual Industrials Conference
Published: 2021-08-02 (Crawled : 15:00) - globenewswire.com
WSO | $440.6 6.54% 0.55% 780K
|
Producer Manufacturing
|
| O: 0.24%
H: 0.61%
C: -0.65%
trial conference
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.36%
H: 0.75%
C: -0.18%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.02%
H: 0.21%
C: -0.12%
ARCT 4 | $26.98 -3.4% -3.44% 270K
|
Health Technology
|
| O: 6.36%
H: 9.92%
C: 5.16%
vaccine trial approval sars-cov-2
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.02 33.33% -8.85% 97K
|
Health Technology
|
| O: 1.71%
H: 1.8%
C: -0.12%
fda phase 1 therapy trial authorized t-cell
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
RNA | News M | $25.09 -0.2% -0.14% 560K
|
Health Technology
|
| O: 0.76%
H: 5.74%
C: 4.3%
fda phase 1 trial clearance
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.